In [107] and others have elucidated that AAT inhibits TMPRSS2 in a similar fashion to protease AAT inhibitory mechanism and its inhibitory activity was comparable with camostat mesylate, a drug that inhibits TMPRSS2, which is currently under investigation in several clinical trials to treat COVID-19 [108]. Here, TMPRSS2 is linked to COVID-19.